Dexcom’s first-of-its-kind NIL program welcomes 13 new athletes and eight returning team members, including San Diego State University basketball standout Miles Byrd and Alabama A&M University’s ...
Benzinga reached out to DexCom for comments and is yet to hear from them. A surprise FDA inspection found Dexcom made an unauthorized design change to the G7 glucose monitoring device, with internal ...
DexCom (DXCM) faces GLP-1 disruption as it targets non-insulin Type 2 CGM growth. Read here for a detailed invesment analysis ...
San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing just under ...
DexCom posted another quarter of robust top-line growth that leaves the firm on track to meet our full-year expectations, and we’re standing behind our $315 fair value estimate. Importantly, DexCom’s ...
Dexcom shares plunged on disappointing revenue and weak guidance. The stock was down 13% for the year as of Thursday's close. Dexcom makes continuous glucose monitors for patients with diabetes. In ...
Diabetes is a disease in which there is too much sugar in a person's blood. Type 2 diabetes is most common and is caused by factors such as obesity or lack of exercise. Rising obesity rates are a big ...
We recently published 10 Stocks Bleeding Early. DexCom, Inc. (NASDAQ:DXCM) is one of the worst-performing stocks on Monday. DexCom fell for a fifth straight day on Monday, shedding 3.82 percent to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results